Rifabutin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 21: | Line 21: | ||
'''| [[Rifabutin clinical studies|Clinical Studies]]''' | '''| [[Rifabutin clinical studies|Clinical Studies]]''' | ||
'''| [[Rifabutin dosage and administration|Dosage and Administration]]''' | '''| [[Rifabutin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Rifabutin how supplied|How Supplied]]''' | '''| [[Rifabutin how supplied|How Supplied]]''' | ||
'''| [[Rifabutin labels and packages|Labels and Packages]]''' | '''| [[Rifabutin labels and packages|Labels and Packages]]''' | ||
Revision as of 02:13, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages